Amicus Therapeutics Inc. said Donald Hayden Jr. retired as a director.
The Cranbury, N.J.-based biotechnology company said Hayden had been on its board for 12 years.
Discover more about S&P Global’s offerings
Amicus Therapeutics director retires
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Essential IR Insights Newsletter - February 2023
Insight Weekly: US bank margins rise; smartphone shipments drop; coal miners book strong sales
Amicus Therapeutics Inc. said Donald Hayden Jr. retired as a director.
The Cranbury, N.J.-based biotechnology company said Hayden had been on its board for 12 years.